This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 312
- Registration Number
- NCT03448419
- Locations
- 🇺🇸
University Of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸The Center for Clinical Trials, Inc., Saraland, Alabama, United States
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 315
- Registration Number
- NCT03448406
- Locations
- 🇺🇸
Cox Medical Center South, Springfield, Missouri, United States
🇺🇸Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Acacia Medical Research Institute,LLC, Sugar Land, Texas, United States
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 267
- Registration Number
- NCT03449381
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT03433898
- Locations
- 🇯🇵
Kanagawa Cancer Center, Kanagawa, Yokohama, Japan
🇯🇵Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 175
- Registration Number
- NCT03429543
- Locations
- 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Atlanta Center, Atlanta, Georgia, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT03422068
- Locations
- 🇪🇸
Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇬🇧Southampton General Hospital, Southampton, United Kingdom
Greek NIS Spiolto ELLACTO
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: MaxSpiolto® Respimat® 160 Characters...
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1360
- Registration Number
- NCT03419962
- Locations
- 🇬🇷
Metropolitan, Patra, Greece
🇬🇷Metroplitan, Athens, Greece
🇬🇷Diavalkaniko, Volos, Greece
This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 54
- Registration Number
- NCT03414008
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65406
- Registration Number
- NCT03405363
- Locations
- 🇩🇰
Aarhus Universitets hospital Skejby, Aarhus, Denmark
This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03403439
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany